Alkermes (ALKS) Expected to Announce Earnings on Thursday

Alkermes (NASDAQ:ALKS) is expected to issue its quarterly earnings data before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of $0.80 per share and revenue of $379.74 million for the quarter. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 22.15% and a return on equity of 24.92%. On average, analysts expect Alkermes to post $2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alkermes Stock Performance

NASDAQ ALKS opened at $35.94 on Wednesday. The firm’s fifty day moving average price is $30.49 and its two-hundred day moving average price is $28.87. The stock has a market cap of $5.84 billion, a PE ratio of 18.43, a PEG ratio of 1.83 and a beta of 0.49. Alkermes has a fifty-two week low of $22.90 and a fifty-two week high of $36.45. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.03 and a current ratio of 3.45.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ALKS. The Goldman Sachs Group boosted their price objective on shares of Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. StockNews.com raised shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Stifel Nicolaus raised shares of Alkermes from a “hold” rating to a “buy” rating and upped their price target for the company from $25.00 to $36.00 in a research report on Tuesday, November 5th. HC Wainwright reaffirmed a “neutral” rating and set a $46.00 price target on shares of Alkermes in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. cut their price target on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Alkermes presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.25.

Insider Buying and Selling

In other Alkermes news, EVP Craig C. Hopkinson sold 144,419 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the sale, the executive vice president now owns 57,875 shares of the company’s stock, valued at $2,056,298.75. This trade represents a 71.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Christian Todd Nichols sold 5,208 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total transaction of $151,813.20. Following the completion of the sale, the senior vice president now directly owns 60,703 shares in the company, valued at approximately $1,769,492.45. This trade represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 323,608 shares of company stock worth $10,854,725 in the last 90 days. 4.89% of the stock is owned by company insiders.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.